A Mimicking Esophageal Cancer After Liver Transplant for Hepatocellular Carcinoma: A Rare Posttransplant Metastasis.
Liver transplant is now considered to be a successful treatment modality for early hepatocellular carcinoma. In addition, advances in immunosuppressive therapy have greatly prolonged posttransplant survival of patients with hepatocellular carcinoma. However, both the posttransplant physiologic condition and immunosuppressive therapy affect the patient's natural immunity, resulting in accumulating and more problematic complications. Three years after a male patient with hepatocellular carcinoma underwent living-donor liver transplant, he presented with esophageal metastasis from recurrence of hepatocellular carcinoma. This is an extremely rare complication, perhaps with an ominous prognosis, and, to the best of our knowledge, the first such case to be published in the English literature.
From the Department of Thoracic Surgery, China Medical University Hospital, Taichung, Taiwan and the School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Jian-Xun
JX
Chen
Long-Bin
LB
Jeng
Yu-Sen
YS
Lin
Ting-Yu
TY
Lu
Pei-Yu
PY
Kao
Hsin-Yuan
HY
Fang
D000328:Adult; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000556:secondary* / Q000601:surgery*; D016099:Endoscopy, Gastrointestinal; D004938:Esophageal Neoplasms / Q000556:secondary*; D017809:Fatal Outcome; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects* / Q000379:methods; D019520:Living Donors; D008297:Male; D009364:Neoplasm Recurrence, Local; D049268:Positron-Emission Tomography; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome